BioNTech SE (Nasdaq: BNTX), referred to as “BioNTech” or the “Company,” held its Annual General Meeting (AGM) on May 17, 2024. The virtual assembly saw representation from 87.51% of the share capital. All 14 agenda items presented were approved by a significant majority of shareholders.
“The past few years marked a leap in competence for BioNTech,” said Helmut Jeggle, Chairman of the Supervisory Board. “With the development and commercialization of a leading COVID-19 vaccine, BioNTech has proven its ability to achieve targeted objectives. Today, BioNTech’s strong financial position provides an excellent foundation for its transformation into a multi-product company, focusing particularly on achieving commercial readiness in oncology.”
“2023 was a year of significant progress: We maintained a leading position in the COVID-19 vaccine market, published promising data for our oncology pipeline candidates, and launched potentially registrational trials. We also strengthened our organization to prepare for the next growth phase, especially regarding our planned oncology product launches,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We believe our therapies under development have the potential to complement or replace established cancer treatments in many areas once approved.”
Details of the voting results for all agenda items are available on the Annual General Meeting 2024 website under the ‘Voting Results’ section. Prof. Ugur Sahin’s speech and the presentation slides can be found in the ‘Speeches and Presentations’ section on the same site.
BioNTech SE is a global next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech utilizes a wide array of computational discovery and therapeutic drug platforms for the rapid development of innovative biopharmaceuticals. Its broad oncology product portfolio includes individualized and off-the-shelf mRNA-based therapies, innovative CAR T cells, protein-based therapeutics, targeted cancer antibodies, ADC therapeutics, and small molecules. Leveraging its mRNA vaccine expertise and manufacturing capabilities, BioNTech, in collaboration with various partners, is developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline. BioNTech’s global partnerships include collaborations with Biotheus, DualityBio, Fosun Pharma, Genentech (a member of the Roche Group), Genevant, Genmab, MediLink, OncoC4, Pfizer, and Regeneron.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include, but are not limited to, BioNTech’s financial position, research and development programs, and preparations for potential oncology product launches. These forward-looking statements are based on BioNTech’s current expectations and beliefs about future events and are not guarantees. They involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.
Review the risks and uncertainties under “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2024, and subsequent filings with the SEC, available on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date of this release. BioNTech disclaims any intention or responsibility to update or revise any forward-looking statements due to new information, future developments, or otherwise, except as required by law.
